Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formul...
Sunitinib is indicated for the following conditions:
University of Calgary, Calgary, Alberta, Canada
Pfizer UK, London, United Kingdom
Radboud UMC, Nijmegen, Netherlands
Rhode Island Hospital, Providence, Rhode Island, United States
Children's Hospital Colorado, Aurora, Colorado, United States
University of Colorado Hospital, Aurora, Colorado, United States
Children's Hospital of Atlanta, Atlanta, Georgia, United States
Local Institution - 0260, Belo Horizonte, Minas Gerais, Brazil
Harbin Medical University - Cancer Hospital, Harbin, Heilongjiang, China
Local Institution - 0172, Changsha, Hunan, China
OHSU Knight Cancer Institute, Portland, Oregon, United States
Univ of Alabama at Birmingham; UAB Comprehensive Cancer Ctr, Birmingham, Alabama, United States
HonorHealth Research Institute - Pima - Virginia G. Piper Cancer Care Network, Scottsdale, Arizona, United States
University of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute, Little Rock, Arkansas, United States
Alaska Urological, Anchorage, Alaska, United States
CARTI Cancer Center, Little Rock, Arkansas, United States
Centro de Investigación Pergamino S.A, Buenos Aires, Argentina
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.